Skip to main content
Clinical Trials/NCT00252395
NCT00252395CompletedPhase 4

Effects of Electronic Prescribing on Safety and Quality in Hospital-Based Ambulatory Are: a Randomised Controlled Trial

Sunnybrook Health Sciences Centre2 sites in 1 country40 target enrollmentStarted: August 2005Last updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
40
Locations
2
Primary Endpoint
Total prescribing error, as measured by the number of call backs received from pharmacists.

Study Overview

Brief Summary

All reliably evaluated POE systems to date have been desktop computer based, but now there is widespread use and acceptance among physicians of PDA devices for a variety of purposes. Clinicians report that drug information on a PDA improved their access to information and efficiency while reducing their self perceived error rates6. The use of these devices for information retrieval in clinical settings is expected to grow as wireless communication becomes more ubiquitous and as more applications become available6,7. During the past decade there has been a growing awareness of several issues aimed at promoting safer health care for our patients - point of care information technology is one of the keys.

To this end we have worked with a Canadian company, Drugmagnet, to develop and implement PDA-based electronic prescribing system within a major Canadian academic health centre. This is a cluster randomised trial, in which access to and use of the e-prescribing system is switched on and off for randomly chosen weeks, thus time serves as the randomized element.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Single Group
Primary Purpose
Ect
Masking
None

Eligibility Criteria

Ages
0 Years to — (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • active staff physician at Sunnybrook & Women's College HSC

Exclusion Criteria

  • inadequate prescribing practice (minimum number)

Outcomes

Primary Outcomes

Total prescribing error, as measured by the number of call backs received from pharmacists.

Secondary Outcomes

  • c) Pack errors
  • b) Dosing and route of administration errors
  • a) Interactions
  • d) Legibility errors

Investigators

Sponsor Class
Other

Study Sites (2)

Loading locations...

Similar Trials